Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
Venugopal MenonAnirudh KumarDivyang R PatelJulie St JohnJeffrey RiesmeyerGovinda WeerakkodyGiacomo RuotoloKathy E WolskiEllen McErleanPaul C CremerStephen J NichollsA Michael LincoffSteven E NissenPublished in: BMJ open diabetes research & care (2020)
Despite a favorable increase in HDL, and decreases in LDL and HbA1c levels in patients with DM, we observed no benefits of treatment with evacetrapib on prespecified clinical outcomes in this high-risk population.